medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 3

<< Back Next >>

Ann Hepatol 2013; 12 (3)

Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review

Lieveld FI,van Vlerken LG, Siersema PD, van Erpecum KJ

Language: English
References: 39
Page: 380-391
PDF size: 142.05 Kb.


ABSTRACT

Introduction. Poor adherence to treatment for various chronic diseases is a frequent phenomenon. Current guidelines for the treatment of chronic hepatitis B (HBV) and hepatitis C (HCV) recommend optimal adherence, since it has been suggested that poor adherence is associated with an increased risk of virological failure. We aimed to give an overview of studies exploring adherence to combination treatment (PEG-interferon plus ribavirin) for HCV and nucleos(t)ide analogues for HBV. Material and methods. A systematic review was conducted using the databases PubMed, Embase, Cochrane Library and Web of Knowledge. Search terms included “adherence” or “compliance” combined with “hepatitis B”, “hepatitis C” or “viral hepatitis”. Results. The final selection included 19 studies (13 HCV, 6 HBV). Large differences in patient numbers and adherence assessment methods were found between the various studies. For HCV mean adherence varied from 27 to 97%, whereas the proportion of patients with ≥ 80% adherence varied from 27 to 96%. Mean adherence reported in HBV studies ranged from 81 to 99%, with 66 to 92% of patients being 100% adherent. For both HCV and HBV studies, the highest adherence rates were reported in studies using self-report whereas lower adherence rates were reported in studies using pharmacy claims. Poor adherence to treatment was associated with an increased risk of virological failure. Conclusion. Non-adherence to treatment in chronic viral hepatitis is not a frequent phenomenon. However, given the increased risk of virological failure in poorly adherent patients, clinicians should routinely address adherence issues in all patients treated for chronic viral hepatitis.


REFERENCES

  1. Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol 2008; 22: 991-1008.

  2. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20-9.

  3. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002; 97: 2886-95.

  4. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stagespecific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-31.

  5. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.

  6. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.

  7. Poordad F, McCone J Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.

  8. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.

  9. Weiss JJ, Brau N, Stivala A, Swan T, Fishbein D. Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research. Aliment Pharmacol Ther 2009; 30: 14-27.

  10. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-97.

  11. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ 1999; 160: 31-7.

  12. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.

  13. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.

  14. Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? Clin Pharmacol Ther 1989; 46: 163-8.

  15. Wagner JH, Justice AC, Chesney M, Sinclair G, Weissman S, Rodriguez-Barradas M. Patient- and provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence. J Clin Epidemiol 2001; 54(Suppl. 1): S91-S98.

  16. Marcellin P, Chousterman M, Fontanges T, Ouzan D, Rotily M, Varastet M, Lang JP, et al. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver Int 2011; 31: 516-24.

  17. Wagner G, Chan OK, Garnett J, Ghosh-Dastidar B, Bhatti L, Goetz MB, Witt M. Patient Characteristics Associated with HCV Treatment Adherence, Treatment Completion, and Sustained Virologic Response in HIV Coinfected Patients. AIDS Res Treat 2011; 2011: 903480.

  18. Weiss JJ, Bhatti L, Dieterich DT, Edlin BR, Fishbein DA, Goetz MB, Yu K, et al. Hepatitis C patients’ self-reported adherence to treatment with pegylated interferon and ribavirin. Aliment Pharmacol Ther 2008; 28: 289-93.

  19. Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 2007; 19: 741-7.

  20. Rodis JL, Kibbe P. Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy. Gastroenterol Nurs 2010; 33: 368-73.

  21. Lo RV III, Amorosa VK, Localio AR, O’Flynn R, Teal V, Dorey- Stein Z, Kostman JR, et al. Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Infect Dis 2009; 48: 186-93.

  22. Lo RV III, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R. Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Ann Intern Med 2011; 155: 353-60.

  23. Mitra D, Davis KL, Beam C, Medjedovic J, Rustgi V. Treatment Patterns and Adherence among Patients with Chronic Hepatitis C Virus in a US Managed Care Population. Value Health 2010.

  24. Baran RW, Bhor M, Dietz B, Laitinen D. Poor adherence to treatment witg pegylated interferon/ribavirin in patients with chronic hepatitis C infection is associated with detrimental health outcomes. Hepatology 2009; 50: 653A.

  25. Smith SR, Wahed AS, Kelley SS, Conjeevaram HS, Robuck PR, Fried MW. Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother 2007; 41: 1116-23.

  26. Evon DM, Esserman DA, Ramcharran D, Bonner JE, Fried MW. Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. J Psychosom Res 2011; 71: 349-56.

  27. Evon DM, Esserman DA, Rao TB, Bonner JE, Fried MW, Golin CE. Patient missed doses and treatment non-persistence during peg/ribavirin therapy for chronic hepatitis C: Implications for triple therapy and beyond. Hepatology 2011; 54: 438A.

  28. Alam I, Stainbrook T, Cecil B, Kistler KD. Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry. Aliment Pharmacol Ther 2010; 32: 535-42.

  29. Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok AS. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol 2011; 54: 12-8.

  30. Chotiyaputta W, Hongthanakorn C, Oberhelman K, Fontana RJ, Licari T, Lok AS. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs (VBT). J Viral Hepat 2012; 19: 205-12.

  31. Berg T, Marcellin P, Zoulim F, Moller B, Trinh H, Chan S, Suarez E, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic- hepatitis B virus infection. Gastroenterology 2010; 139: 1207-17.

  32. Hilleret MN, Larrat S, Stanke-Labesque F, Leroy V. Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough? J Hepatol 2011; 55: 1468-9.

  33. Sogni P, Carrieri MP, Fontaine H, Mallet V, Vallet-Pichard A, Trabut JB, Meritet JF, et al. The role of adherence in virological suppression in patients receiving anti-HBV analogues. Antivir Ther 2012; 17: 395-400.

  34. Giang L, Selinger CP, Lee AU. Evaluation of adherence to oral antiviral hepatitis B treatment using structured questionnaires. World J Hepatol 2012; 4: 43-9.

  35. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009; 119: 3028-35.

  36. Hungin AP, Hill C, Molloy-Bland M, Raghunath A. Systematic review: Patterns of proton pump inhibitor use and adherence in gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012; 10: 109-16.

  37. Simpson RJ Jr., Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol 2010; 4: 462-71.

  38. Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav 2010; 14: 731-47.

  39. Press N, Tyndall MW, Wood E, Hogg RS, Montaner JS. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2002; 31(Suppl. 3): S112- S117.




2020     |     www.medigraphic.com